- Home
- DIBS vs EDIT Comparison
DIBS vs EDIT Comparison
Compare DIBS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DIBS | EDIT |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.9M | 202.1M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | DIBS | EDIT |
|---|---|---|
| Price | $5.84 | $2.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $7.00 | $4.50 |
| AVG Volume (30 Days) | 165.0K | ★ 2.0M |
| Earning Date | 02-27-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,422,000.00 | $46,383,000.00 |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $2.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.49 | N/A |
| 52 Week Low | $2.30 | $0.91 |
| 52 Week High | $6.63 | $4.54 |
Technical Indicators
Market Signals| Indicator | DIBS | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 45.17 |
| Support Level | $5.69 | $2.05 |
| Resistance Level | $6.20 | $2.43 |
| Average True Range (ATR) | 0.28 | 0.15 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 54.88 | 31.47 |
Price Performance
Historical ComparisonAbout DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.